| Not Yet Recruiting | A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as Fir NCT07502027 | Huazhong University of Science and Technology | Phase 4 |
| Not Yet Recruiting | Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma NCT07059611 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Not Yet Recruiting | A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN) NCT07518147 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 |
| Not Yet Recruiting | IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advan NCT07483567 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 |
| Recruiting | Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanc NCT07431281 | AstraZeneca | Phase 3 |
| Recruiting | SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure NCT07311408 | Jingdong Zhang | Phase 2 |
| Not Yet Recruiting | Study of ACC-1898 in Adult Participants With Advanced Solid Tumors NCT07252661 | AccSalus Biosciences, Inc. | Phase 1 |
| Enrolling By Invitation | Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for the Treatment of Patients With Gas NCT07139951 | Mayo Clinic | Phase 2 |
| Recruiting | Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction A NCT07182565 | West China Hospital | Phase 1 / Phase 2 |
| Recruiting | To Evaluate the Efficacy of CT041 in Sequential Treatment After First-line Treatment of Advanced Gastric/Esoph NCT07179484 | Beijing GoBroad Hospital | — |
| Recruiting | A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanc NCT07152405 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Ju NCT07072351 | West China Hospital | Phase 1 / Phase 2 |
| Recruiting | Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Juncti NCT07102901 | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 |
| Not Yet Recruiting | MAIC of Fruquintinib Plus Paclitaxel Versus Ramucirumab Plus Paclitaxel in Advanced G/GEJ Adenocarcinoma NCT07144995 | Sun Yat-sen University | — |
| Not Yet Recruiting | The Efficacy and Safety of Iparomlimab/Tuvonralimab (Anti PD-1/CTLA-4) Combined With Albumin-bound Paclitaxel NCT07139587 | Qingxia Li | N/A |
| Recruiting | A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Ch NCT07043400 | BeOne Medicines | Phase 3 |
| Recruiting | A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors NCT07090499 | Pfizer | Phase 1 |
| Recruiting | Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patie NCT07001748 | ECOG-ACRIN Cancer Research Group | Phase 2 / Phase 3 |
| Recruiting | Real-WorlD ZolbetUximab in Patients With HER-2 Negative and CLaudin 18.2 PosItive MetastatiC AdEnocarcinoma NCT07427992 | European Institute of Oncology | — |
| Not Yet Recruiting | Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Local NCT06942767 | Qilu Pharmaceutical Co., Ltd. | Phase 2 |
| Recruiting | Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer NCT06028737 | Ukrainian Society of Clinical Oncology | Phase 2 / Phase 3 |
| Terminated | A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 NCT07040059 | Aurigene Discovery Technologies Limited | Phase 1 / Phase 2 |
| Not Yet Recruiting | Postoperative Adjuvant Therapy for CT041 Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma Patients NCT06857786 | Peking University | Phase 1 |
| Recruiting | A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First- NCT06764875 | AstraZeneca | Phase 3 |
| Recruiting | BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastr NCT06773312 | Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination NCT06628310 | AbbVie | Phase 2 |
| Active Not Recruiting | Sintilimab in Combination with Chemotherapy ± Local Treatment for Om-G/GEJ NCT06739161 | Jiangsu Cancer Institute & Hospital | Phase 2 |
| Terminated | A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMAR NCT06560645 | Prelude Therapeutics | Phase 1 |
| Withdrawn | Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 NCT06341647 | GC Cell Corporation | Phase 1 |
| Not Yet Recruiting | A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilim NCT06586294 | Akeso | Phase 1 / Phase 2 |
| Recruiting | Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanc NCT06560528 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Completed | A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors NCT06549816 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Recruiting | Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatm NCT06324357 | Boehringer Ingelheim | Phase 1 / Phase 2 |
| Not Yet Recruiting | Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemo NCT06454435 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors NCT06157892 | Seagen, a wholly owned subsidiary of Pfizer | Phase 2 |
| Recruiting | Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected NCT06265285 | Mayo Clinic | Phase 2 |
| Recruiting | Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma NCT06340711 | Weill Medical College of Cornell University | Phase 2 |
| Recruiting | AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer NCT06196697 | Harbin Medical University | Phase 2 |
| Terminated | A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or NCT05567835 | Baylor College of Medicine | Phase 2 |
| Recruiting | DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Ade NCT06221748 | RemeGen Co., Ltd. | Phase 2 / Phase 3 |
| Active Not Recruiting | ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarci NCT06206733 | AskGene Pharma, Inc. | Phase 3 |
| Recruiting | A Study of KK2269 in Adult Participants With Solid Tumors NCT06266299 | Kyowa Kirin Co., Ltd. | Phase 1 |
| Active Not Recruiting | A Study of Minimally Invasive Proximal Gastrectomy Versus Minimally Invasive Total Gastrectomy for Gastric and NCT06243757 | Memorial Sloan Kettering Cancer Center | — |
| Completed | Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesopha NCT07529613 | National Cancer Center Hospital East | Phase 1 / Phase 2 |
| Active Not Recruiting | Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastr NCT05836584 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasi NCT05802056 | Mayo Clinic | Phase 1 |
| Recruiting | Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcin NCT06155383 | RemeGen Co., Ltd. | Phase 2 |
| Recruiting | A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors NCT06131840 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Recruiting | Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells for Gastric/Gastroesophageal Junction Adenocarcinoma NCT06353152 | Peking University | Phase 1 |
| Recruiting | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Meta NCT06047379 | Neonc Technologies, Inc. | Phase 1 / Phase 2 |
| Terminated | Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinom NCT06206278 | LianBio LLC | Phase 2 |
| Recruiting | A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer NCT06038578 | Toray Industries, Inc | Phase 2 |
| Withdrawn | A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors NCT05678205 | Artiva Biotherapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. NCT06792435 | Evopoint Biosciences Inc. | Phase 1 / Phase 2 |
| Recruiting | Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With A NCT05476796 | UNICANCER | Phase 2 |
| Recruiting | Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limit NCT05753306 | Mayo Clinic | Phase 2 |
| Recruiting | Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer NCT05709574 | University of Arizona | Phase 2 |
| Unknown | Efficacy and Safety of Neoadjuvant Chemoradiation Plus Serplulimab in Patients With Locally Advanced Adenocarc NCT05918419 | Peking Union Medical College Hospital | Phase 2 |
| Recruiting | Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cance NCT06121700 | Fudan University | Phase 2 |
| Recruiting | Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection NCT05334069 | Alliance for Clinical Trials in Oncology | — |
| Terminated | A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HE NCT05311176 | Imugene Limited | Phase 2 |
| Unknown | Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression NCT05472857 | Suzhou Immunofoco Biotechnology Co., Ltd | Phase 1 |
| Unknown | Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid Tumors NCT05393986 | Peking University | Phase 1 |
| Completed | Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy NCT05394740 | National Cancer Center Hospital East | Phase 1 / Phase 2 |
| Completed | GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer NCT05419362 | Genome & Company | Phase 2 |
| Active Not Recruiting | Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untre NCT05111626 | Amgen | Phase 3 |
| Active Not Recruiting | Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2 NCT05052801 | Amgen | Phase 3 |
| Active Not Recruiting | First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer NCT05156866 | TORL Biotherapeutics, LLC | Phase 1 |
| Active Not Recruiting | Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitab NCT05034887 | National Cancer Center Hospital East | Phase 2 |
| Active Not Recruiting | First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer NCT05159440 | TORL Biotherapeutics, LLC | Phase 1 |
| Terminated | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresect NCT04683939 | BioNTech SE | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) NCT05002127 | ALX Oncology Inc. | Phase 2 / Phase 3 |
| Unknown | Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Adv NCT05111444 | Fudan University | Phase 2 |
| Completed | iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma NCT04808791 | AHS Cancer Control Alberta | Phase 2 |
| Completed | A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcino NCT05008783 | Akeso | Phase 3 |
| Terminated | A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 NCT04933227 | Hoffmann-La Roche | Phase 2 |
| Recruiting | Folfox+Irinotecan+Chemort In Esophageal Cancer NCT04656041 | Massachusetts General Hospital | Phase 2 |
| Unknown | Real-world Data (RWD) of Ramucirumab Plus Paclitaxel NCT04915807 | Hallym University Medical Center | — |
| Recruiting | Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Rese NCT04850729 | Nanfang Hospital, Southern Medical University | — |
| Active Not Recruiting | Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarci NCT04704934 | Daiichi Sankyo | Phase 3 |
| Completed | Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HE NCT04499924 | Seagen Inc. | Phase 2 / Phase 3 |
| Completed | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies NCT04772989 | Arcus Biosciences, Inc. | Phase 1 |
| Active Not Recruiting | A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 NCT04661150 | Hoffmann-La Roche | Phase 2 |
| Active Not Recruiting | Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis NCT04762953 | University of California, Irvine | Phase 2 |
| Completed | Financial Navigation Intervention in Improving Financial and Clinical Outcomes in Patients With Newly Diagnose NCT03986502 | Fred Hutchinson Cancer Center | N/A |
| Completed | Esophageal cAncer Screening Trial NCT04609813 | Changhai Hospital | — |
| Recruiting | HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT) NCT04447352 | Krankenhaus Nordwest | Phase 3 |
| Recruiting | NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer NCT04615013 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection NCT04581473 | CARsgen Therapeutics Co., Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NCT04140526 | OncoC4, Inc. | Phase 1 / Phase 2 |
| Terminated | A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persi NCT04510285 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | A Study of Sigvotatug Vedotin in Advanced Solid Tumors NCT04389632 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Active Not Recruiting | Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ NCT04375605 | Universitätsmedizin Mannheim | Phase 3 |
| Unknown | Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterat NCT05019794 | LianBio LLC | Phase 2 |
| Recruiting | Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies NCT04361708 | University of Chicago | Phase 1 |
| Completed | Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid NCT04344795 | Tempest Therapeutics | Phase 1 |
| Withdrawn | MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma NCT03739801 | University of Southern California | Phase 1 / Phase 2 |
| Unknown | Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metast NCT04263870 | Sichuan University | Phase 2 |
| Active Not Recruiting | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (K NCT04152499 | Klus Pharma Inc. | Phase 1 / Phase 2 |
| Recruiting | A Multicenter Cancer Biospecimen Collection Study NCT04510129 | Cofactor Genomics, Inc. | — |
| Completed | Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer NCT04208958 | Vedanta Biosciences, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Telehealth for the Self-Management of Dietary Quality of Life in Patients After Stomach Cancer Surgery NCT05203627 | City of Hope Medical Center | N/A |
| Recruiting | Registry Platform Gastric/Esophageal Cancer (SAPHIR) NCT04290806 | iOMEDICO AG | — |
| Completed | A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastr NCT04161781 | Memorial Sloan Kettering Cancer Center | — |
| Terminated | Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma NCT04089904 | University of Chicago | Phase 2 |
| Terminated | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors NCT04032704 | Seagen Inc. | Phase 2 |
| Active Not Recruiting | Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gast NCT03979131 | Vall d'Hebron Institute of Oncology | Phase 2 |
| Terminated | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumo NCT04060342 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | Phase 1 |
| Recruiting | Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer NCT04018872 | Dallas VA Medical Center | Phase 2 |
| Unknown | Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Gastroesophageal Junction NCT03986385 | Hebei Medical University | Phase 3 |
| Suspended | Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Und NCT03604991 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Unknown | Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma NCT03966118 | P. C. Thuss-Patience | Phase 2 |
| Completed | A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma NCT03802591 | CStone Pharmaceuticals | Phase 3 |
| Completed | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas NCT03894618 | Shattuck Labs, Inc. | Phase 1 |
| Completed | A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-l NCT03852251 | Akeso | Phase 1 / Phase 2 |
| Terminated | A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With C NCT03735290 | Mendus | Phase 1 |
| Completed | TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Ade NCT03686488 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer NCT03724851 | MedPacto, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junct NCT03760822 | Federation Francophone de Cancerologie Digestive | Phase 2 |
| Completed | Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive NCT03615326 | Merck Sharp & Dohme LLC | Phase 3 |
| Terminated | A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gast NCT03707028 | Elevar Therapeutics | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness NCT03421288 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Phase 2 |
| Terminated | Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors NCT03511222 | Washington University School of Medicine | Phase 1 |
| Withdrawn | Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroes NCT03592407 | City of Hope Medical Center | Phase 2 |
| Completed | OPPOSITE: Outcome Prediction of Systemic Treatment in Esophagogastric Carcinoma NCT03429816 | University Hospital Heidelberg | N/A |
| Completed | Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma NCT03395847 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Unknown | Concurrent Neoadjuvant Chemoradiotherapy Plus Trastuzumab in the Treatment of Siewert II ，III of Human Epiderm NCT03368131 | Hebei Medical University | Phase 2 |
| Unknown | A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally A NCT03349866 | Hebei Medical University | Phase 2 |
| Recruiting | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid NCT03175224 | Apollomics Inc. | Phase 2 |
| Completed | Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction o NCT03196232 | George Albert Fisher | Phase 2 |
| Active Not Recruiting | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastati NCT03170960 | Exelixis | Phase 1 |
| Unknown | PEN-866 in Patients With Advanced Solid Malignancies NCT03221400 | Tarveda Therapeutics | Phase 1 / Phase 2 |
| Terminated | Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers NCT03122548 | Aduro Biotech, Inc. | Phase 2 |
| Terminated | Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Ga NCT02530437 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal NCT02898077 | Eli Lilly and Company | Phase 3 |
| Terminated | A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors NCT02952989 | Seagen Inc. | Phase 1 |
| Terminated | Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gas NCT03019588 | Merck Sharp & Dohme LLC | Phase 3 |
| Active Not Recruiting | Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery NCT02962063 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Completed | Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gas NCT02830594 | City of Hope Medical Center | Phase 2 |
| Completed | Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer NCT02891447 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in A NCT02864381 | Gilead Sciences | Phase 2 |
| Completed | Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With NCT02730546 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcin NCT02628951 | Samsung Medical Center | Phase 2 |
| Completed | Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progr NCT02589496 | Samsung Medical Center | Phase 2 |
| Completed | A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Ma NCT02572687 | Eli Lilly and Company | Phase 1 |
| Completed | A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer NCT02514551 | Eli Lilly and Company | Phase 2 |
| Completed | A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma NCT02539225 | Eli Lilly and Company | Phase 2 |
| Completed | A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Can NCT02443883 | Eli Lilly and Company | Phase 2 |
| Completed | A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal J NCT02370498 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma NCT03083613 | Chinese Academy of Medical Sciences | Phase 2 |
| Completed | Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage NCT02389751 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Ju NCT02335411 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach NCT02314117 | Eli Lilly and Company | Phase 3 |
| Terminated | MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Rec NCT02391038 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Completed | Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer NCT02128243 | AIO-Studien-gGmbH | Phase 2 |
| Completed | A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer NCT02082210 | Eli Lilly and Company | Phase 1 / Phase 2 |
| Unknown | Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric Aden NCT02193594 | Peking University | Phase 2 / Phase 3 |
| Completed | Gastric Microperfusion in Patients Undergoing Gastroesophageal Resections NCT02077673 | Rigshospitalet, Denmark | — |
| Unknown | MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer NCT02007148 | International Group of Endovascular Oncology | Phase 2 |
| Completed | Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Jun NCT01962246 | Hebei Medical University | Phase 2 / Phase 3 |
| Completed | Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophagea NCT01196390 | National Cancer Institute (NCI) | Phase 3 |
| Unknown | Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced NCT01379807 | Grupo Gallego de Investigaciones Oncologicas | Phase 2 |
| Unknown | Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma NCT00964080 | Mebiopharm Co., Ltd | Phase 1 / Phase 2 |
| Unknown | Phase II Study of Neoadjuvant Taxotere, Cisplatin, and 5-Fluorouracil in Patients With Gastric or Gastroesopha NCT00763646 | McGill University | Phase 2 |
| Completed | Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gast NCT00515411 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Approved For Marketing | Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Tempora NCT02307812 | Eli Lilly and Company | — |